Exhibit A

The Parties' Proposed Constructions of Disputed Claim Terms and Supporting Evidence for U.S. Patent No. 8,450,475

Disputed Claim Terms	Claim No.	Allergan's Proposed	Allergan's Supporting Evidence	Defendants' Proposed	Defendants' Supporting
		Construction		Construction	Evidence
uncrosslinked	(Claims 1,	water soluble	<u>INTRINSIC</u>	water soluble	<u>INTRINSIC</u>
HA	2, 4, 9, 18,	HA (i.e.,	Claims 1-3, 9, 10, 12-16,	HA (i.e.,	
	31, 33, 34,	uncrosslinked	18, 19, 27-31, 33, 34, 36,	uncrosslinked	3:10-13;
	36)	HA and/or	Abstract,	HA and/or	5:5-13;
		lightly	Col. 1, 1. 66 to Col. 2, 1. 6,	lightly	7:6-9;
		crosslinked	Col. 2, Il. 15-19,	crosslinked	7:29-35;
		HA)	Col. 3, Il. 7-21,	HA) that is	13:8-26
		,	Col. 3, 1. 54 to Col. 4, 1. 3,	added to the	
			Col. 4, 11. 4-27, 36-40,	crosslinked HA	Communications
			Col. 5, Il. 5-13, 15-21, 47-58,	portion of the	from file
			Col. 6, 11. 23-35,	composition	wrapper of
			Col. 6, 1. 66 to Col. 7, 1. 3,	•	Application
			Col. 7, 11. 4-35,		No. 12/393,768
			Col. 8, 11. 13-22, 50-63,		including:
			Col. 8, 1. 61 to Col. 9, 1. 8,		Office Action
			Col. 11, 1l. 45-56,		dated
			Col. 13, 1l. 9-10,		5/31/2011;
			Col. 17, 1l. 1-25,		Response to
			Col. 18, 11. 14-21,		Office Action
			Example 2, Col. 13, 11. 9-18.		dated 11/9/2011;

					Office Action
			Communications from file		dated
			wrapper of Application		2/3/2012;
			No. 12/393,768 including:		Response to
			Office Action dated		Office Action
			5/31/2011;		dated 7/30/2012;
			Response to Office Action		Office Action
			dated 11/9/2011;		dated
			Office Action dated		11/19/2012;
			2/3/2012;		Applicant
			Response to Office Action		Initiated
			dated 7/30/2012;		Interview
			Office Action dated		Summary on
			11/19/2012;		2/6/2013;
			Applicant Initiated Interview		Response to
			Summary on 2/6/2013;		Final Office
			Response to Final Office		Action dated
			Action dated 2/19/2013.		2/19/2013.
			<u>EXTRINSIC</u>		<u>EXTRINSIC</u>
			VAL0037758-64		
					VAL0060472
					at 75 (5:1-26)
free HA	(Claims	water soluble	INTRINSIC	water soluble	<u>INTRINSIC</u>
	27-29)	HA (i.e.,	Claims 1-3, 9, 10, 12-16,	HA (i.e.,	
		uncrosslinked	18, 19, 27-31, 33, 34, 36,	uncrosslinked	3:10-13;
		HA and/or	Abstract,	HA and/or	5:5-13;
		lightly	Col. 1, l. 66 to Col. 2, l. 6,	lightly	7:6-9;

crosslinked	Col. 2, Il. 15-19,	crosslinked	7:29-35;
HA)	Col. 3, Il. 7-21,	HA) that is	13:8-26
	Col. 3, 1. 54 to Col. 4, 1. 3,	added to the	
	Col. 4, 11. 4-27, 36-40,	crosslinked HA	Communications
	Col. 5, Il. 5-13, 15-21, 47-58,	portion of the	from file
	Col. 6, 11. 23-35,	composition	wrapper of
	Col. 6, 1. 66 to Col. 7, 1. 3,		Application
	Col. 7, 11. 4-35,		No. 12/393,768
	Col. 8, Il. 13-22, 50-63,		including:
	Col. 8, 1. 61 to Col. 9, 1. 8,		Office Action
	Col. 11, ll. 45-56,		dated
	Col. 13, ll. 9-10,		5/31/2011;
	Col. 17, ll. 1-25,		Response to
	Col. 18, 11. 14-21,		Office Action
	Example 2, Col. 13, Il. 9-18.		dated 11/9/2011;
			Office Action
	Communications from file		dated
	wrapper of Application		2/3/2012;
	No. 12/393,768 including:		Response to
	Office Action dated		Office Action
	5/31/2011;		dated 7/30/2012;
	Response to Office Action		Office Action
	dated 11/9/2011;		dated
	Office Action dated		11/19/2012;
	2/3/2012;		Applicant
	Response to Office Action		Initiated
	dated 7/30/2012;		Interview
	Office Action dated		Summary on
	11/19/2012;		2/6/2013;

			Applicant Initiated Interview		Response to Final Office
			Summary on 2/6/2013;		
			Response to Final Office		Action dated
			Action dated 2/19/2013.		2/19/2013.
			EXTRINSIC VAL0037758-64		EXTRINSIC
					VAL0060472
					at 75 (5:1-26)
НА	(Claims 1,	HA that forms a	INTRINSIC	HA that has	INTRINSIC
crosslinked	31, 34)	macromolecular	Claims 1, 4-7, 9, 10, 18, 19,	been covalently	
with 1,4-		structure	27, 31, 34,	modified with	2:15-19;
butanediol		resulting from	Col. 1, 11. 23-34,	BDDE to form	3:10-19;
diglycidyl		chemical	Col. 1, 1. 66 to Col. 2, 1. 6,	a	4:4-6;
ether		linking of HA	Col. 2, 11. 7-19, 50-58,	macromolecular	4:62-5:4;
(BDDE)	(Claim 18)	by BDDE	Col. 3, 11. 7-41,	structure that is	7:4-35;
			Col. 3, 1. 61 to Col. 4, 1. 27	water-insoluble,	7:49-53;
hyaluronic			Col. 4, 11. 62-65,	such that the	9:25-39;
acid (HA)			Col. 5, 11. 5-13,	degree of	12:37-39
component			Col. 5, 11. 47-58,	crosslinking is	
crosslinked			Col. 6, 11. 55-65,	at least about	U.S. Patent No.
with 1,4-			Col. 7, 11. 20-35, 47-53,	2% and is up to	8124120 B2
butanediol			Col. 9, 11. 6-33, 40-56,	about 20%	
diglycidyl			Col. 9, 1. 66 to Col. 10, 1. 9.		Communications
ether (BDDE)	(Claim 27)		Col. 12, 11. 17-49,		from file
			Col. 16, ll. 40-46, 56-61,	"Degree of	wrapper of
(BDDE)-			Col. 18, 11. 14-21.	crosslinking" as	Application
crosslinked				used herein has	No. 12/393,768

hyaluronic	Communications from file	the same	including:
acid	wrapper of Application	construction as	Office Action
	No. 12/393,768 including:	agreed by the	dated
	Office Action dated	parties.	5/31/2011;
	5/31/2011;		Response to
	Response to Office Action		Office Action
	dated 11/9/2011;		dated 11/9/2011;
	Office Action dated		Office Action
	2/3/2012;		dated
	Response to Office Action		2/3/2012;
	dated 7/30/2012;		Response to
	Office Action dated		Office Action
	11/19/2012;		dated 7/30/2012;
	Applicant Initiated Interview		Office Action
	Summary on 2/6/2013;		dated
	Response to Final Office		11/19/2012;
	Action dated 2/19/2013.		Applicant
			Initiated
	<u>EXTRINSIC</u>		Interview
	Merriam-Webster Online		Summary on
	Dictionary and Thesaurus,		2/6/2013;
	(http://www.merriamwebster.		Response to
	com/).		Final Office
	[AGNHA00096828-		Action dated
	96829]		2/19/2013.
	Random House Webster's		EXTRINSIC
	College Dictionary, 2nd		
	edition, 2001, page 296.		VAL0060472

			[AGNHA00096824]		at 73 (2:9-16)
					VAL0059980 at 81 (2:26-30)
					VAL0060006
					at
					VAL0060008
					(3:14-18), VAL0060013
					(8:1-9)
					(0.1))
					VAL0060285
					at 87 ([0011])
stable	(Claims 1,	resists chemical	INTRINSIC	A sterile	<u>INTRINSIC</u>
	18, 27, 31,	and physical	Claims 1, 10, 18, 19, 27,	composition	
	34)	decomposition	31, 34,	that maintains	3:41-46;
			Abstract,	one of the	4:41-48;
			Col. 1, ll. 42-59,	following	5:39-44;
			Col. 2, 11. 7-32, 42-48	aspects:	8:4-13;
			Col. 3, 11. 42-46,	transparent	13:19-26;
			Col. 4, 11. 41-48,	appearance, pH,	14:1-24
			Col. 5, ll. 31-46,	extrusion force	
			Col. 6, 11. 23-31, 55-65,	and/or	Communications
			Col. 7, 11. 42-64,	rheological	from file
			Col. 8, Il. 4-13,	characteristics,	wrapper of
			Col. 10, 11. 15-33,	hyaluronic acid	Application
			Col. 11, ll. 14-44,	(HA)	No. 12/393,768

Col. 13, l. 27 to Col. 14, l. 1-	concentration,	including:
23.	sterility,	Office Action
23.	osmolarity, and	dated
Examples 2 & 3.	lidocaine	5/31/2011;
Communications from file	concentration,	Response to
	,	Office Action
wrapper of Application No.	after being	
12/393,768	stored at about	dated 11/9/2011;
including:	25C for about	Office Action
Office Action dated	two months	dated
5/31/2011;		2/3/2012;
Response to Office Action		Response to
dated 11/9/2011;		Office Action
Office Action dated		dated 7/30/2012;
2/3/2012;		Office Action
Response to Office Action		dated
dated 7/30/2012;		11/19/2012;
Office Action dated		Applicant
11/19/2012;		Initiated
Applicant Initiated Interview		Interview
Summary on 2/6/2013;		Summary on
Response to Final Office		2/6/2013;
Action dated 2/19/2013.		Response to
		Final Office
EXTRINSIC		Action dated
'795 patent, claims 29-36.		2/19/2013.
775 patent, ciamis 27 50.		2/1//201J.
Random House Webster's		EXTRINSIC
College Dictionary, 2 nd		<u>LATITUTOIC</u>
edition, 2001, page 1190.		

[AGNHA00096822-96827 at 96826]	
Oxford Concise English Dictionary, 11th edition, 2008, page 1402.	
[AGNHA00096817-96821at 96820]	

Exhibit B

The Parties' Proposed Constructions of Disputed Claim Terms and Supporting Evidence for U.S. Patent No. 8,357,795

Disputed	Claim No.	Allergan's	Allergan's Supporting	Defendants'	Defendants'
Claim Terms		Proposed	Evidence	Proposed	Supporting
		Construction		Construction	Evidence
hyaluronic	(Claim 1)	HA that forms a	<u>INTRINSIC</u>	HA that has	<u>INTRINSIC</u>
acid (HA)		macromolecular	Claims 1, 4, 5, 12, 22, 23,	been covalently	
component		structure	Col. 1, ll. 23-34, 66-67,	modified with a	<u>2:50-58;</u>
crosslinked		resulting from	Col. 2, Il. 7-19, 50-58,	crosslinking	<u>3:10-19;</u>
with a		chemical	Col. 3, 11. 7-19, 22-41, 62-65,	agent to form a	3:66-4:1;
crosslinking		linking of HA	Col. 4, Il. 5-30, 13-29,	macromolecular	<u>5:46-52;</u>
agent		by a	Col. 5, 11. 43-46, 53-61,	structure that is	<u>8:4-25;</u>
		crosslinking	Col. 8, 11. 20-24,	water-insoluble,	<u>10:16-24;</u>
		agent	Col. 9, l. 64 to Col. 10, l. 15,	such that the	<u>15:34-37</u>
			Example 2,	degree of	
			Col. 10, ll. 16-45,	crosslinking is	U.S. Patent No.
			Col. 13, l. 12 to Col. 14, l.	at least about	8124120 B2
			25.	2% and is up to	
				about 20%.	
			Communications from file		EXTRINSIC
			wrapper of Application	"Degree of	
			No. 12/393,884 including:	crosslinking" as	VAL0060472
			Office Action dated	used herein has	at 73 (2:9-16)
			5/31/2011;	the same	

dated 9/29/2011; Office Action dated 12/27/2011; Applicant Initiated Interview Summary dated 1/24/2012; Applicant Initiated Interview Summary dated 4/9/2012; Declaration of Lebreton dated 3/7/2012 and 6/14/2012;	agreed by the parties within the '475 Patent.	VAL0059980 at 81 (2:26-30), 82-83 (4:45 - 5:3) VAL0060006 at VAL0060008 (3:14-18), VAL0060013 (8:1-9)
Response to Final Office Action dated 6/14/2012. EXTRINSIC Merriam-Webster Online Dictionary and Thesaurus, (http://www.merriamwebster. com/). [AGNHA00096828] Random House Webster's College Dictionary, 2nd edition, 2001, page 296.		VAL0060285 at 87 ([0011])